INTRODUCTION {#s1}
============

α-Thalassemia results from a genetic defect in α-globin chain synthesis, often as a consequence of deletional mutations and less frequently due to non-deletional types of mutations \[[@ref1],[@ref2]\]. α-Thalassemias may occur worldwide; however, they are seen more commonly among populations in South East Asia, the Mediterranean region, and the Middle East \[[@ref1]\]. The α-globin gene is located on the short arm of chromosome 16 (16p13.3) and normally there are 4 α-globin gene copies in an individual, with 2 in each allele \[[@ref3]\]. The phenotype of α-thalassemias is directly related to the number of α-globin genes affected. α+-Thalassemias designate the status of deletion in one of the paired α-globin genes (-α/αα), whereas in α0-thalassemias both of the paired α-globin genes are deleted (\--/αα). Heterozygous α+-thalassemia usually causes a silent carrier state. On the other hand, heterozygous α0-thalassemia (\--/α) and homozygous α+-thalassemia (-α/-α) result in hematological findings similar to α-thalassemia trait, except for the Hb A2 value, which is at the normal level or below the normal level in α-thalassemia. The co-existence of both α+-thalassemia and α0-thalassemia (-α/\--) results in hemoglobin H (Hb H) disease \[[@ref1]\]. There are also non-deletional types of mutations (αTα) resulting in Hb H disease, when a large deletional type of mutation (\--) co-exists in trans (αTα/\--) \[[@ref4],[@ref5]\].

The most common deletional mutations causing α+-thalassemia are -α3.7 and -α4.2, whereas the common deletional mutations causing α0-thalassemias are of 20.5-kb deletion, approximately 17.5-kb deletion (-MED-I), greater than 26.5-kb deletion (-MED-II), and approximately 18-kb deletion (-SEA) \[[@ref1],[@ref4],[@ref6]\]. MED-II has previously been reported in a few Turkish families and from other Mediterranean populations \[[@ref4]\].

In this study, the hematological and molecular data of 35 patients with Hb H disease from a single center were analyzed and reported in order to identify the genotypes of Hb H disease and genotype-phenotype correlations, and also to create awareness that Hb H disease is not a rare entity in Turkey.

MATERIALS AND METHODS {#s2}
=====================

Of the 788 patients who were diagnosed with thalassemia between 1981 and 2014 at our institution, 138 (17.5%) were diagnosed with Hb H disease ([Table 1](#t1){ref-type="table"}). Unfortunately, from those 138 patients only a total of 35 had genotype data available; those 35 were included in the current study. Splenomegaly was detected at diagnosis, during physical examination, or by ultrasonography in 40% of the patients with Hb H disease. The transfusion histories of patients with Hb H were recorded from patients' files. Of the patients with Hb H disease, 18% received erythrocyte transfusion at least once, and 82% had no transfusion history at diagnosis and received no transfusion during follow-up. The number of transfusions ranged between 1 and 24. One patient was on a chronic transfusion program, whereas the other patients were transfused occasionally. Ethical committee approved this study.

Excluding the patients with Hb H disease, of the individuals screened for α-thalassemia mutations, 78 were found to carry an α-thalassemia mutation. The indications of α-thalassemia mutational screening among those 78 individuals were either having hypochromic microcytic erythrocytes, with normal iron status and Hb A2 below 3.5%, or being the available parent of a patient with Hb H disease.

Results of hematological studies and red cell indices were analyzed. For discussion purposes, values prior to splenectomy or erythrocyte transfusion were taken into consideration. Hemoglobin A2, Hb F, and Hb H values were measured with the previously described methods \[[@ref7]\] or high-performance liquid chromatography with the Bio-Rad Variant II system. Supravital stains for Hb H inclusions were examined in all cases \[[@ref8]\].

Prior to 2008, α-thalassemia mutations were identified with previously described methods \[[@ref7],[@ref8],[@ref9],[@ref10],[@ref11],[@ref12],[@ref13]\]. After 2008, mutation analyses for the α-globin gene were evaluated with the α-Globin Strip-Assay (ViennaLab, Austria), based on the reverse-hybridization technique used for detection of the 21 most common α-thalassemia mutations in the Mediterranean region. Of the 35 patients with Hb H disease, 25 have been reported previously \[[@ref7]\].

The obtained data were evaluated with SPSS 21 (IBM Corp., Armonk, NY, USA). Normality test was performed to determine if the data were distributed in a normal fashion. For comparison between groups of more than 2, one-way ANOVA test was used. Statistical significance was determined as p values \<0.05.

RESULTS {#s3}
=======

Of the 35 patients with Hb H disease, the age range was 1.5-50 years at diagnosis (mean: 15.9±12.9 years). The mean values of red blood cell indices at diagnosis are summarized in [Table 2a](#t1){ref-type="table"}. A total of 10 different genotypes were detected in 35 patients with Hb H disease [(Tables 2b](#t2){ref-type="table"} and [2c](#t3){ref-type="table"}.).

Of the 35 patients with Hb H disease, 22 (62.8%) and 18 (51.4%) were found to have -α3.7 or \--20.5 alleles, respectively ([Table 3](#t4){ref-type="table"}). The most common genotype was -α3.7/\--20.5 in 10 (28.6%) of the patients, followed by -α3.7/\--26.5 in 6 (17.1%) and -α3.7/\--17.5 in 6 (17.1%). The most common 3 genotypes were distributed among 22 of the 35 patients, representing 62.8% of all genotypes found in patients with Hb H disease. The numbers of Hb H patients having other genotypes were too small to make any statistical analysis; therefore, comparison of the hematological data was made only among the patients with the 3 most common above-mentioned genotypes.

Statistical analyses of the mean values of red cell indices showed no significant difference among these 3 common genotypes. Hemoglobin F level was found significantly higher in -α3.7/\--17.5 patients (p=0.041), whereas Hb H levels were significantly lower among patients with this genotype compared to the -α3.7/\--20.5 and -α3.7/\--26.5 genotypes (p=0.036). Hemoglobin A2 levels were similar among these 3 genotypes.

Of the patients with Hb H disease, 26 (74.3%) were found to have deletional types of mutations, whereas 9 (25.7%) were found to have non-deletional types of mutations. Comparison of the hematological data of the Hb H patients showed that the group of patients with a genotype consisting of non-deletional types of mutations with a large trans deletion (ααT/\--) had statistically lower hemoglobin values (p=0.007) compared to those who had deletional types of mutations with a large trans deletion (-α/\--) ([Table 4](#t5){ref-type="table"}). On the other hand, the mean of Hb H levels was significantly higher in the former patients (18.1± 8.3 vs. 7.4±4.7; p=0) than the latter ([Table 4](#t5){ref-type="table"}). In the examination of the 78 individuals with α-thalassemia mutations other than Hb H disease, the most common genotype was -α3.7/αα in 31 patients (39.7%) ([Table 5](#t6){ref-type="table"}). The most common non-deletional genotype was α(PA-1)/αα in 5 of the individuals (6.4%). Of the 78 subjects, 34 (43.5%) and 21 (26.9%) were found to have -α3.7 or \--20.5 alleles, respectively ([Table 5](#t6){ref-type="table"}).

DISCUSSION {#s4}
==========

The incidence of deletional α-thalassemia (-α/αα) among newborns screened by globin gene mapping from samples obtained from cord blood at birth has been reported to be 3.6% in Turkey \[[@ref14]\]. In other reports, the chromatographic analyses of cord blood samples of newborns in Turkey suggested that -α/αα or (αTα) thalassemia incidence was between 2.9% and 4.1% \[[@ref15],[@ref16]\].

In a recent report from Antakya-Hatay, a city in the southern part of Turkey, 300 individuals with moderate anemia, microcytosis, and normal iron levels were tested for α-thalassemia by the aid of α-globin strip assay; of these, 97 were found to have at least 1 mutation in 4 of the α-globin genes \[[@ref17]\]. Of these patients, the most common mutation was -α3.7 (57.3%) \[[@ref17]\]. Similarly, Öner et al. and Çürük reported -α3.7 as the most common α-thalassemia gene that was associated with Hb H disease in 25 and 32 patients, respectively \[[@ref7],[@ref18]\]. Our study is compatible with the above stated previously published data pointing out that -α3.7 has been the most common genotype among patients with Hb H disease (62.8%).

In our study, among Hb H patients, the second most common allele was \--20.5 (51.4%). This finding is in accordance with the other reports from Turkey \[[@ref7],[@ref18],[@ref19]\]. A hydrops fetalis case due to α-thalassemia associated with homozygosity of \--20.5 was also previously reported from Turkey \[[@ref20]\].

In the current study, the -MED-II deletion (\--26.5) was found as the third most common allele among patients with Hb H disease (25.7%), which was followed by \--MED-I deletion (\--17.5) at 17%. Contrary to our observation, the \--MED-I mutation (\--17.5) has been reported as the second most common type of allele by Guvenc et al. with 15.11% frequency among the population of Adana, a city in the southern part of Turkey \[[@ref21]\]. This is probably related to the homogeneity of the population studied in that publication.

The \--MED-II deletion has been known as a genotype more common among Turkish populations \[[@ref4]\], and it was found as the third most common allele in our study.

All of these studies suggest that the molecular pathology of Hb H disease is heterogeneous and, according to our study, the most common genotypes associated with Hb H in 35 patients who were referred to us from all over Turkey are as follows: -α3.7/\--20.5 (28.6%), -α3.7/\--26.5 (17.1%), and -α3.7/\--17.5 (17.1%) ([Table 2b](#t1){ref-type="table"}).

In the current study, 25.7% of the patients with Hb H disease who had a combination of large deletional and non-deletional (ααT/\--) mutations were found to have statistically significantly lower Hb and higher Hb H levels compared to those of patients having combinations of large and small deletional (-α/\--) types of mutations ([Table 4](#t2){ref-type="table"}). This finding was compatible with the previously published data \[[@ref1],[@ref2],[@ref3]\]. This study revealed the presence of 3 different non-deletional types of mutations, namely the (-5nt), PA2, and C59 mutations. It seemed that the most common non-deletional type of combination involved in Hb H was (-5nt/\--), which was found in 3 patients (8.6%) in the current study. Contrary to this, α (PA-2)/\--MED-II was the most frequent non-deletional combination in a regional study by Çürük \[[@ref18]\]. It was interesting that in spite of the presence of 2 intact α-globin genes, homozygosity for PA-2 mutation (α PA-2/α PA-2) resulted in severe Hb H disease in 2 patients ([Table 2c](#t3){ref-type="table"}); this was discussed elsewhere \[[@ref7]\].

In this study, we did not find any of the previously described α-gene mutations from Turkey, such as -THAI, \--FIL, init.cd, Cd 19, Hb Icaria, Hb Pakse, or Hb Koya Dora \[[@ref14],[@ref16],[@ref17],[@ref18],[@ref19],[@ref21]\]. In a previous study from our center, the rate of unidentifiable mutations among individuals with α-thalassemia mutations was reported to be 2.72% \[[@ref22]\]. In this study, all of the mutations among patients with Hb H disease were known mutations. In the previous study from our center, among individuals with α-thalassemia major, the most common 3 mutations were distributed among 69.39% of the patients \[[@ref22]\]. In this study, it was shown that the most common 3 genotypes associated with Hb H accounted for almost 63% of the study group.

In the previous reports by Altay and by Akar and Altay, related to National Hemoglobinopathy Registry data, Hb H was reported to be 3.6% (n=103) of all hemoglobinopathies in Turkey \[[@ref22],[@ref23]\]. In our cohort study from a single center, it was shown that Hb H disease was diagnosed in 17.5% of the total 650 thalassemic patients ([Table 1](#t4){ref-type="table"}). The latest figure for α-thalassemia major in Turkey was reported to be 57% of 5500 patients with hemoglobinopathies \[[@ref24],[@ref25]\]. Therefore, according to the data of our center as stated above, the total number of Hb H patients in Turkey should be around 550. The discrepancy in the rates of Hb H between 2002 data and the current study may derive from the higher awareness of the disorder in some centers in recent years, more accurate diagnoses, and/or developments in the diagnostic tools of Hb H disease and/or an increase in referral rates of anemic patients from peripheral to tertiary centers like ours. Therefore, if the figure of the current study reflects a more accurate value of the number of Hb H cases, we may expect to diagnose more patients in the near future.

In conclusion, as our center is a referral center in the mid-Anatolia region with a patient profile from all over the Turkey, the results of our study may represent the Hb H disease rates among the overall Turkish population. Some of the data of this study were in agreement with previous reports \[[@ref7],[@ref8],[@ref9],[@ref16],[@ref17],[@ref18],[@ref19],[@ref20]\], and our current study also indicated that the molecular spectrum of α-thalassemias is quite heterogeneous in Turkey, as all together 9 deletional and non-deletional mutations and 10 combinations of them were found to be associated with Hb H disease. In previous reports, the mutational spectra were reported to be less heterogeneous among smaller populations, such as among Cypriots and Iraqi Turks \[[@ref26],[@ref27]\]. Although in this study the molecular pathology of Hb H disease has been addressed, the frequencies of rare genotypes associated with α-thalassemia requires more patients and further population studies, since most of the individuals screened for that purpose in the current study were parents of the patients with Hb H disease, a limiting factor in prediction of the population frequencies of several genotypes. This study also showed that Hb H disease is not uncommon in Turkey; therefore, this disease should be kept in mind in discussion of microcytic anemias and all efforts should be made for correct diagnosis of α-thalassemias. Detection of new cases will be helpful in determining the allele frequencies of different α-thalassemia mutations.
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###### The distribution of β- and α-thalassemias between 1981 and 2014 in the Hacettepe University Division of Pediatric Hematology.

![](TJH-32-136-g1)

###### The age and hematological data of patients with Hb H disease with molecular diagnosis.
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###### The age and hematological data of patients with Hb H disease with the 3 most common genotypes.
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###### The age and hematological data of patients with Hb H disease associated with rare mutations.
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###### Distribution of mutations in 35 patients with Hb H (70 chromosomes).
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###### The comparison between hematological parameters of patients with Hb H disease with deletional and non-deletional types of mutations.
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###### The distribution of deletional and non-deletional types of α-thalassemia mutations in 78 individuals.
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